HCW BiologicsHCWB +1.82%39 Interest Coverage is 26.21 as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 377 Biotechnology companies, HCW Biologics ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. HCW Biologics's
Operating Income
for the
three
months ended in Mar. 2026 was $3.25 Mil. HCW Biologics's Interest Expense for the
three
months ended in Mar. 2026 was $-0.12 Mil.
HCW Biologics's interest coverage for the quarter that ended in Mar. 2026 was 26.21.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for HCW Biologics's Interest Coverage or its related term are showing as below:
HCWB's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
HCW Biologics Interest Coverage Related Terms
HCW Biologics Interest Coverage Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HCWB vs MTVA, INTI, HOOK: Interest Coverage Comparison
For the Biotechnology subindustry, HCW Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Interest Coverage of 26.21 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HCW Biologics and its competitors. This is 100% below median its historical median of 10,000.00. According to the industry distribution chart, HCW Biologics ranks #999999 out of 377 companies in the Biotechnology industry.
Is HCW Biologics' Interest Coverage too high?
HCW Biologics' current Interest Coverage of 26.21 is 100% below median its 10-year median of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. HCW Biologics' value of 26.21 is 75.3% below this industry median. Based on the distribution chart, HCW Biologics ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Interest Coverage compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #999999 out of 377 companies for Interest Coverage. This places HCW Biologics in the lower half of its industry. The industry median Interest Coverage is 106.07. HCW Biologics' value of 26.21 is 75.3% below this benchmark. While the company's 10-year median is 10,000.00 vs. the industry median of 106.07, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Interest Coverage of 26.21 is 75.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Interest Coverage is 26.21, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.12 — trading 84.6% below its estimated fair value. The current Interest Coverage is 26.21, which is 100% below median its 10-year median of 10,000.00 and 75.3% below the Biotechnology industry median of 106.07. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Interest Coverage is 26.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.12 is trading 84.6% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Interest Coverage: 26.21 (100% below median its 10-year median of 10,000.00)
GF Value™: $7.29 vs. price of $1.12 (84.6% below fair value)
Industry Position: 75.3% below the Biotechnology median (#999999 of 377)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
